Therapeutic effect of preS2-containing vaccine in an infant infected with a vaccine-escape variant (Thr127) of hepatitis B virus

International Hepatology Communications

Volumn 6, Issue 3-4, 1997, Pages 158-165

  Noto, H ^a   Fujii, Y ^b   Takahashi, K ^c   Kishimoto, S ^c   Mishiro, S ^c  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kikugawa General Hospital   (Japan)

^c Shinagawa ku   (Japan)

Author keywords

escape mutant; hepatitis B virus; immunoprophylaxis; mother to infant transmission; preS2; vaccine

Indexed keywords

BIKEN HB; HEBSBULIN; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; RHB VACCINE; TGP943; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CASE REPORT; CLINICAL TRIAL; ESCAPE BEHAVIOR; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MOTHER CHILD RELATION; NEWBORN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS TRANSMISSION;

EID: 0031040489     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4346(96)00343-X     Document Type: Article

References (16)

1. [1] Shiraki K. Vertical transmission of hepatitis B virus and its prevention in Japan. In: Nishioka K, Suzuki H, Mishiro S, Oda T, editors. Viral Hepatitis and Liver Disease. Tokyo: Springer-Verlag, 1994; 530-532.
2. [2] Fujisawa Y, Kuroda S, Van Herd PM, Schellekens H, Kakinuma A. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). Vaccine 1990; 8: 192-198.
3. [3] Kuroda S, Fujisawa Y, Iino S, Akahane Y, Suzuki H. Induction of protection level of anti-preS2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). Vaccine 1991; 9: 163-169.
4. [4] Suzuki H, Iino S, Shiraki K, Akahane Y, Okamoto H, Domoto K, Mishiro S. Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing. Vaccine 1994; 12: 1090-1096.
5. [5] Iizuka H, Ohmura K, Ishijima A, Satoh K, Tanaka T, Tsuda F, Okamoto H, Miyakawa Y, Mayumi M. Correlation between anti-HBc titers and HBV DNA in blood units without detectable HBsAg. Vox Sang 1992; 63: 107-11.
6. [6] Pol S, Driss F, Michel M-L, Nalpas B, Berthelot P, Brechot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994; 343: 1460-1463.
7. [7] Wen Y-M, Wu X-H, Hu D-C, Zhang Q-P, Guo S-Q. Hepatitis B vaccine and anti-HBs complex for vaccine therapy. Lancet 1995; 345: 1575-1576.
8. [8] Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-329.
9. [9] Harrison TJ, Hopes EA, Oon CJ, Zanetti AR, Zuckerman AJ. Independent emergence of a vaccine-induced escape mutant of hepatitis B virus. J Hepatol 1991; 13(S4): S105-107.
10. [10] Fujii H, Moriyama K, Sakamoto M, Kondo T, Yasuda K, Hiraizumi Y, Yamazaki M, Sakaki Y, Okochi K, Nakajima E. Gly145 to Arg substitution in HBs antigen of immune escape mutants of hepatitis B virus. Biochem Biophys Res Commun 1992; 184: 1152-1157.
11. [11] Hino K, Okuda M, Hashimoto O, Ishiko H, Okazaki M, Fujii K, Hanada H, Okita K. Glycine-to-arginine substitution at codon 145 of HBsAg in two infants born to hepatitis B e antigen-positive carrier. Dig Dis Sci 1995; 40: 566-570.
12. [12] Okamoto H, Yano K, Nozaki Y, Matsui A, Miyazaki H, Yamamoto K, Tsuda F, Machida A, Mishiro S. Mutations within the S gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. Pediatr Res 1992; 32: 264-268.
13. [13] Harrison TJ, Oon CJ, Zuckerman AJ. A novel antibody escape variant (Ala 144) of hepatitis B virus in an identical twin before selection in the mother. In: Nishioka K, Suzuki H, Mishiro S, Oda T, editors. Viral Hepatitis and Liver Disease. Tokyo: Springer-Verlag, 1994; 248-251.
14. [14] Machida A, Okamoto H, Tsuda F, Tanaka T, Domoto K, Mishiro S. Anti-preS2 neutralizes the hepatitis B virus variant with a vaccine-escape mutation at the amino acid position 126 or 145 within the S gene. Int Hepatol Commun 1994; 2: 186-189.
15. [15] Milich DR, Thornton GB, Neurath AR, Kent SB, Michel M-L, Tiollais P, Chisari FV. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985; 228: 1195-1199.
16. [16] Surya IGP, Kishimoto S, Sudaryat S, Tsuda F, Hamid A, Takahashi K, Suwignyo S, Hashimoto K, Mulyanto, Mishiro S. Prevention of mother-to-infant transmission of hepatitis B virus with use of a preS2-containing vaccine in Bali, Indonesia. Vaccine Research 1996; 5: 203-213.